PLX — Protalix Biotherapeutics Balance Sheet
0.000.00%
- $170.01m
- $139.73m
- $52.74m
Annual balance sheet for Protalix Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 39 | 22.2 | 44.6 | 34.8 | 30.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.44 | 4.59 | 5.27 | 2.91 | 8.84 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 61.7 | 44.9 | 69.9 | 60.1 | 66.7 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 9.92 | 9.64 | 10.9 | 10 | 12.6 |
| Other Long Term Assets | |||||
| Total Assets | 73.7 | 55.8 | 84.4 | 73.4 | 82.3 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 33.2 | 32.4 | 45.5 | 25.6 | 26.5 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 79.7 | 66.4 | 50.9 | 30.2 | 34.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -6.04 | -10.6 | 33.6 | 43.2 | 48.2 |
| Total Liabilities & Shareholders' Equity | 73.7 | 55.8 | 84.4 | 73.4 | 82.3 |
| Total Common Shares Outstanding |